Table 2.
Medical Cannabis Use Following 3 and 6 Months of Treatment
| MC use |
3 Months (n=31) |
6 Months (n=22) |
|---|---|---|
| Frequency of MC use | Mean±SD | Mean±SD |
| Average MC uses/week | 8.31±6.83 | 7.24±4.62 |
| Average MC days used/week | 5.04±2.06 | 5.06±1.90 |
| Average MC times used/day | 1.60±0.82 | 1.44±0.87 |
| Cannabinoid exposurea | Mean±SD | Mean±SD |
|---|---|---|
| Average THC mg/week |
52.31±124.34 |
54.68±82.66 |
| Average CBD mg/week | 126.95±265.72 | 119.78±149.63 |
| Urinalysis | n (%) or mean±SD | n (%) or mean±SD |
|---|---|---|
| Positive THC screen |
15 (48.4) |
15 (68.2) |
| THC/creatinine (ng/mg) ratiob | 113.09±80.99 | 147.60±212.59 |
| Number of MC products used | Median (IQR) | Median (IQR) |
|---|---|---|
| Median total MC products | 3 (2.00) | 3 (2.25) |
| Routes of administration (product type)c | n (%) or median (IQR) | n (%) or median (IQR) |
|---|---|---|
| Inhalation (e.g., flower, vape oil) |
21 (67.7) |
15 (68.2) |
| Oromucosal (e.g., sublingual oil) |
14 (45.2) |
9 (40.9) |
| Oral (e.g., edibles, capsules) |
12 (38.7) |
9 (40.9) |
| Cutaneous (e.g., cream, lotion) |
2 (6.5) |
1 (4.5) |
| Transdermal (e.g., patch) |
0 (0.0) |
0 (0.0) |
| Transmucosal (e.g., suppository) |
0 (0.0) |
0 (0.0) |
| Median total reported routes | 1 (1) | 1.5 (1) |
a
Constituent information on MC products was available for n=22 at 3-month follow-up and n=15 at 6-month follow-up.
b
At the 3-month follow-up, one of the 15 samples that tested positive for THC metabolites was unable to be processed by Quest Diagnostics (n=14 for these analyses); at the 6-month follow-up, all MC patients who had a positive urine screen had further quantification analyses.
c
Patients could report multiple routes of administration.
CBD, cannabidiol; IQR, interquartile range; THC, Δ-9-tetrahydrocannabinol.